Major Nasal Decongestant

Description

Major® No Drip Nasal Mist is a nasal spray formulation containing oxymetazoline hydrochloride at a concentration of 0.05%. This product is designed for intranasal administration and provides relief for up to 12 hours. Each bottle contains 1 fluid ounce (30 mL) of the solution. The product is identified by the National Drug Code (NDC) 0904-7427-30.

Uses and Indications

This drug is indicated for the temporary relief of nasal congestion associated with the common cold, hay fever, and upper respiratory allergies. It also provides temporary relief from sinus congestion and pressure. The formulation works by shrinking swollen nasal membranes, facilitating easier breathing.

There are no teratogenic or nonteratogenic effects associated with this drug as per the available data.

Dosage and Administration

Before the initial use, the protective cap must be removed from the tip of the bottle, and the pump should be primed by firmly depressing it several times.

For administration, the bottle should be held with the thumb at the base and the nozzle positioned between the first and second fingers. The nozzle should be inserted into the nostril without tilting the head. The rim of the nozzle must be fully depressed with a firm and even stroke while the patient sniffs deeply.

After each use, the nozzle should be wiped clean to maintain hygiene.

For adults and children aged 6 to under 12 years (with adult supervision), the recommended dosage is 2 to 3 sprays in each nostril, not to exceed every 10 to 12 hours. It is important not to exceed 2 doses within any 24-hour period. For children under 6 years of age, consultation with a doctor is advised prior to use.

Contraindications

Use is contraindicated in the following situations:

• Use is not recommended for more than three days, as frequent or prolonged use may lead to the recurrence or worsening of nasal congestion.

• The use of this product by more than one person is contraindicated due to the potential risk of spreading infection.

Warnings and Precautions

Healthcare professionals should be aware of the following warnings and precautions associated with the use of this product.

General precautions must be observed to ensure safe usage. It is imperative that the product is not used in excess of the recommended dosage. Users should refrain from utilizing the product for more than three consecutive days, as prolonged or frequent use may lead to a recurrence or worsening of nasal congestion. Patients may experience temporary discomfort, which can manifest as burning, stinging, sneezing, or an increase in nasal discharge. Additionally, it is crucial to note that sharing this container among multiple users may facilitate the spread of infection.

In the event of accidental ingestion, immediate medical assistance should be sought, or the user should contact a Poison Control Center without delay.

Healthcare professionals should advise patients to discontinue use and consult a physician if symptoms persist.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. In the event that symptoms persist, it is advised to stop use and consult a healthcare professional.

Before initiating treatment, patients are encouraged to seek medical advice if they have a history of heart disease, high blood pressure, diabetes, thyroid disease, or if they experience trouble urinating due to an enlarged prostate gland. These conditions may increase the risk of adverse reactions or complicate the management of the medication's effects.

Monitoring for these factors is essential to ensure patient safety and the effective use of the medication.

Drug Interactions

There are no specific drug interactions or laboratory test interactions identified in the available data. Therefore, no recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Major Nasal Decongestant (oxymetazoline hydrochloride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may receive 2 or 3 sprays in each nostril, administered no more frequently than every 10 to 12 hours. It is important to note that the total dosage should not exceed 2 doses within a 24-hour period. For children under 6 years of age, consultation with a healthcare professional is advised prior to use.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The safety of this drug during pregnancy has not been established, and potential risks to fetal outcomes are not fully understood. Therefore, it is essential for women of childbearing potential to seek medical advice to weigh the benefits and risks associated with the use of this medication during pregnancy and lactation.

Lactation

Lactating mothers are advised to stop use and consult a doctor if they are pregnant or breastfeeding. It is recommended that they seek guidance from a health professional prior to using this product. There is no specific data available regarding the excretion of this product in breast milk or its effects on breastfed infants.

Renal Impairment

Renal impairment may necessitate dosage adjustments for patients with reduced kidney function. It is essential to monitor renal function tests regularly in these patients to ensure appropriate management. Specifically, patients with reduced creatinine clearance may require a reduced dose to avoid potential toxicity. Additionally, special considerations should be taken for patients with severe renal impairment to ensure their safety and the efficacy of treatment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be considered as part of standard clinical practice.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to standard protocols for managing suspected cases of drug overdose.

It is essential to monitor patients closely for any signs or symptoms that may arise following an overdose. Common symptoms may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and ensuring hemodynamic stability.

Additionally, the use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent. Consultation with a poison control center or a medical toxicologist is also advisable to determine the most appropriate management strategies based on the specific circumstances of the overdose.

Documentation of the incident, including the substance involved, the amount ingested, and the time of ingestion, is crucial for guiding treatment decisions and ensuring comprehensive patient care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to inform patients that they should not use the product for more than three days and must adhere strictly to the directed dosage. Patients should be made aware that frequent or prolonged use may lead to a recurrence or worsening of nasal congestion.

Providers should also discuss the possibility of temporary discomfort, which may include symptoms such as burning, stinging, sneezing, or an increase in nasal discharge. Additionally, it is crucial to inform patients that sharing this container with others may increase the risk of spreading infection.

Before initiating use, healthcare providers should encourage patients to consult with a doctor if they have any pre-existing conditions, including heart disease, high blood pressure, diabetes, thyroid disease, or difficulties urinating due to an enlarged prostate gland.

Storage and Handling

The product is supplied in packaging that includes specific NDC numbers, which should be referenced for identification. It is essential to store the product at a controlled temperature between 20° and 25°C (68° to 77°F) to maintain its integrity and efficacy.

Healthcare professionals are advised to retain the carton for future reference, as it contains important information regarding the full labeling of the product. Proper handling and storage conditions are crucial to ensure the product remains effective throughout its shelf life.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Major Nasal Decongestant, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)